Meeting
2016 ASCO Annual Meeting
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.
Authors
Sarah Nikiforow
Dana-Farber Cancer Institute, Boston, MA
Sarah Nikiforow , Joana Murad , Heather Daley , Helene Negre , Jake Reder , Charles L. Sentman , Frederic Lehmann , Sarah Snykers , Rachel Allen , Ilene Galinsky , Nikhil C. Munshi , Richard M. Stone , Robert Soiffer , Jerome Ritz , Susanne H.C. Baumeister
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02203825
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS3102)
DOI
10.1200/JCO.2016.34.15_suppl.TPS3102
Abstract #
TPS3102
Poster Bd #
420b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
First Author: Hong-jiu Dai
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Antigen-dependent costimulation to improve T-cell therapy for cancer.
First Author: Christopher C. DeRenzo
Poster
2016 Genitourinary Cancers Symposium
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
First Author: Kevin Mark Slawin